Canaccord Adams Global Growth

RNS Number : 0372X

Oxford Biomedica PLC

07 August 2009

 



For Immediate Release	7 AUGUST 2009

OXFORD BIOMEDICA TO PRESENT AT CANACCORD ADAMS GLOBAL GROWTH CONFERENCE

Oxford, UK - 7 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, is pleased to announce that John Dawson, its Chief Executive Officer, will present a company update on Tuesday, 11 August 2009 at 9.30am ET (2.30pm BST) at the Canaccord Adams 29th Annual Global Growth Conference being held in Boston, MA.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Chief Executive Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
Media/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Elliott Buchanan Communications	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NRAPFMATMMJMBTL